KISQALI FEMARA CO-PACK (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the KISQALI FEMARA CO-PACK drug offered from Novartis Pharmaceuticals Corporation. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
NON-PROPRIETARY NAME: | letrozole and ribociclib |
SUBSTANCE NAME: | |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | |
ROUTE: | |
DOSAGE FORM: | KIT |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2017-05-04 |
END MARKETING DATE: | 0000-00-00 |
KISQALI FEMARA CO-PACK HUMAN PRESCRIPTION DRUG Details:
Item Description | KISQALI FEMARA CO-PACK from Novartis Pharmaceuticals Corporation |
LABELER NAME: | Novartis Pharmaceuticals Corporation |
DEA SCHEDULE: | |
ACTIVE STRENGTH: | () |
START MARKETING DATE: | 2017-05-04 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0078-0909_bbb67312-e5e6-4537-a95c-59c324ab549f |
PRODUCT NDC: | 0078-0909 |
APPLICATION NUMBER: | NDA209935 |